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Sdays, there were no death, follow-up myocardial infarction or stent thrombosis. There
was however 1 case of target vessel revascularization not related to BVS.
Conclusions: These preliminary results suggest that complex lesions can possibly be
successfully treated with BVS. Intravascular ultrasound guidance and meticulous
technique may be important to optimize clinical outcomes.Circulatory Support, Heart Failure, and HOCM
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Percutaneous coronary intervention with a percutaneous left ventricular assist
device support (TandemHeart): 6 years’ experience and outcomes
Pranav Loyalka1, Angelo Nascimbene2, Igor Gregoric3, Biswajit Kar1
1UTHealth Medical School, Houston, TX, 2Texas Heart Institute, Houston, TX,
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Background: We have used the TandemHeart  (Cardiac Assist, Pittsburgh, PA)
percutaneous left ventricular assist device during percutaneous coronary intervention
(PCI) in patients for whom conventional PCI and aorto-coronary bypass would pose
substantial risk due to comorbidities and/or clinical presentation. We present a retro-
spective series of patients and report clinical outcomes with a 6 year follow up
Methods: We retrospectively analyzed data from 626 consecutive PCIs at the Texas
Heart Institute from 2005 to 2011. Among these, we identiﬁed 74 cases performed
with TandemHeart support. Cases were classiﬁed as elective, urgent, emergent, or
emergent salvage according to STS deﬁnitions. To standardize intervention's
complexity, we calculated each patient's SYNTAX score. Ejection fraction prior to the
procedure (EF), left mean atrial pressure prior to PCI (LAP), mean cardiac output
provided by mechanical support (mCO) and length of hemodynamic support provided
for successful weaning (LCS) were recorded. Incidences of 30-day mortality, pro-
longed hospital stay (i.e. hospitalization greater than 14 days), stroke, prolonged
ventilation (i.e. > 24 hours), post-procedural acute kidney injury (i.e. increase of
greater than 0.5 mg/dl in creatinine).
Results: Mortality at 30 days for the elective, urgent, emergent, and emergent salvage
subgroups was 6%, 12%, 22%, and 38%. Anatomic complexity(SYNTAX score),
hemodynamic instability(LAP)and morbidity were collected for each group. In the
elective subgroup LCS was 10.1 days and all patients in this group were successfully
weaned frommechanical support. In the urgent subgroup LCSwas 3.92.6 days and all
patients were successfully weaned from mechanical support. In the emergent subgroup
LCS was 3.92.6 days, and 84% (16/19) patients were successfully weaned from
mechanical support. In the rescue subgroup 67% of the patients (14/22) cardiopul-
monary resuscitation (CPR) was in progress or had recently performed prior to the
procedure, LCS was 6.94.5 days and 54%(12/22) patients were successfully weaned.
Conclusions: TandemHeart-assisted PCI is a valid option for revascularization in
profound cardiogenic shock and extreme-risk elective revascularization.
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Ablation in the Hypertrophic Obstructive Cardiomyopathy: Results from
a Multicenter Registry.
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Background: Percutaneous transluminal septal ablation (PTSMA) is an alternative
treatment to surgery in patients with hypertrophic obstructive cardiomyopathy
(HOCM) with advanced symptoms despite optimal medical treatment, specially under
high surgical risk. However, due to the relatively new introduction of the technique the
very long term results of PTSMA (>10 years) are unknown.
Methods: We have included in the present study consecutive patients with HOCM
treated with PTSMA in 5 centers between 1998 and 2003. We have analyzed clinical,
hemodymanic and echocardiographic data at baseline and follow up.
Results: A total of 45 patients were included, 31 (69%) women and mean age 62.4 14
years. Among those 39 (86.6%) were in NYHA class III or IV. The septum thickness was
21.83.5 mm, maximum basal gradient in echo 7739 mmHg and mitral regurgitationB134 JACC Vol 62/18/Suppl B j October 27–November 1, 2013 jwas at least moderate in 22 (48.8%). In hospitalization 3 pts required permanent pace-
maker implantation and 1 pt had ventricular perforation (by pacing lead) undergoing
surgery. After a median follow up of 12.3 years (11-13.5), 9 pts died and among these 2
pts (4.4%) suffered cardiac death (heart failure and post-transplantation), 2 pts under-
went ICD implantation (the case with perforation and surgery due to subsequent
ventricular tachycardia, and other for primary prevention), 2 underwent cardiac surgery
(endocarditis and severe mitral regurgitation). In the last clinical review NYHA class
was I-II in 39 (86.6%), (p<0.0001), the maximum basal gradient was 1623 mmHg
(p<0.0001) and mitral regurgitation was absent or mild in 34 (75.5%) (p < 0.03).
Conclusions: The results of this study suggest safety and efﬁcacy for PTSMA at
a very long term follow up, over 10 years. A sustained reduction in gradients, mitral
regurgitation and functional class is observed. This treatment was not associated with
signiﬁcant incidence of sudden death or ventricular arrhythmias.
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Early experience of CT angiography in planning alcohol septal ablation (ASA)
for hypertrophic obstructive cardiomyopathy (HOCM)
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Background: ASA is an established treatment for HOCM. Up to 30% have an
unsatisfactory outcome from intended treatment.
Methods: CT images are used to highlight the SAM-septal contact point. Vascular
supply to this area is identiﬁed, the course and origin of these vessels are described.
The target septal is labeled and a 3D angiogram created to deﬁne optimal angiographic
angles. All major epicardial arteries are surveyed to identify any further target vessels
and exclude those with an inappropriate distribution.
Results: 16 patients have undergone CT angiography prior to ASA. The approach to
ASA was changed in 9. CT can identify septal arteries that bifurcate to supply both the
left and right ventricular septum. Contrast injection into the ostium of such arteries
localises to the RV due to the pressure differential between coronary ﬂow to RV and
LV. On balloon occlusion of the LV sub-branch the contrast localises to the target area.
CT can reliably determine the sub-branch that supplies the target area. This has occurred
in 6/16 patients. 3 patients had epicardial artery source other than LAD (circumﬂex,
diagonal, obtuse marginal). 12 patients have received alcohol and have >1 month
review. 11/12 have improved dyspnoea (one has progressive pulmonary ﬁbrosis).
LVOT gradients have decreased by >50% from baseline to a ﬁnal level of <50mmHg
in all. Peak VO2 is improved in all 6 who have undergone 6-month testing.
Conclusions: CT has the ability to describe intricate details of septal arterial anatomy.
Our approach to ASA is changing and contrast localisation is more accurate. Initial
results are very encouraging.TCT Abstracts/POSTER/Circulatory Support, Heart Failure, and HOCM
